|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tagraxofusp (tagraxofusp-erzs) [Elzonris™] is an intravenously administered CD123-directed cytotoxin (composed of human interleukin-3 and a truncated diphtheria toxin payload) that was developed by Stemline Therapeutics, Inc. for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
|
30859413 |
2019 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The performance characteristics of the TCF4/CD123 stain were evaluated in 48 confirmed BPDCN cases.
|
31261288 |
2019 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> CD123-targeted chimeric antigen receptor (CAR) T cell (CART123) for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm has exhibited potential in clinical trials.
|
31417286 |
2019 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The interleukin-3 receptor α subunit, CD123, is expressed in many hematologic malignancies including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
|
31437130 |
2019 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tagraxofusp is an intravenously administered CD123-directed cytotoxin consisting of the fusion of interleukin-3 with a truncated diphtheria toxin payload and was recently approved by the Food and Drug Administration for the treatment of adults and children aged 2 and older with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
|
31465247 |
2019 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given the promising results in early clinical trials, it appears CD123 is the most viable target for BPDCN, and future studies should continue to exploit its expression on BPDCN cells.
|
30715612 |
2019 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Future directions in therapy approaches for patients with BPDCN will include the development of other CD123-targeted agents, agents targeting beyond CD123 and investigation of rational combination approaches of CD123-directed therapy with other therapies.
|
31579499 |
2019 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SL-401 is a targeted therapy directed to CD123, a protein ubiquitously expressed at high level on the surface of BPDCN blasts.
|
29720227 |
2018 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
While the current standard treatment for BPDCN is acute leukemia-based regimen followed by hematopoietic stem cell transplantation for transplant-eligible patients, there are very promising results for CD123 directed therapies.
|
30118336 |
2018 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared to non-cutaneous BPDCN, cutaneous BPDCN was associated with an older median age at onset (72 years versus 45 years, P < 0.05), and higher positivity for CD4 (P < 0.05), CD123 (P < 0.05) and 2-3 pDC markers (89% versus 50%, P = 0.05).
|
28795410 |
2017 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human BDCA2+CD123+CD56+ dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset.
|
25779340 |
2015 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We report about a male patient who suffered from BPDCN with a typical histology and co-expression of CD4/CD123 and a CD56 expression by 80% of the tumour cells.
|
21923812 |
2011 |
|
Blastic plasmacytoid dendritic cell neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the immunohistochemical panel could not distinguish between the varied underlying myeloid disorders, with the exception that CD123 was particularly powerful in recognizing chronic myelomonocytic leukemia and also permitted reclassification of 4 cases as blastic plasmacytoid dendritic cell neoplasm.
|
21228369 |
2011 |